H.C. Wainwright analyst Emily Bodnar initiated coverage of NextCure with a Buy rating and $7 price target. The analyst believe expectations for positive data in Q4 are very low, creating an attractive buying opportunity. The firm says current stock levels indicate that investors are ascribing essentially no value to NextCure’s pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NXTC: